Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
RESEARCH TOOLSreports
Bausch + Lomb Corporation (BLCO) Stock Price & Analysis
66 Followers
BLCO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.62 - $21.95
Previous Close$13.74
Volume1.16M
Average Volume (3M)484.90K
Market Cap
$4.82B
Enterprise Value$9.00B
Total Cash (Recent Filing)$355.00M
Total Debt (Recent Filing)$4.46B
Price to Earnings (P/E)-18.5
Beta0.73
Next Earnings
Aug 01, 2024EPS Estimate
$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding350,992,243
10 Day Avg. Volume486,786
30 Day Avg. Volume484,897
Standard Deviation0.09
R-Squared0.08
Alpha-0.00772
Financial Highlights & Ratios
Price to Book (P/B)-3.88
Price to Sales (P/S)4.92
Price to Cash Flow (P/CF)85.10
P/FCF Ratio42.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit4.49
Enterprise Value/Ebitda24.59
Forecast
1Y Price Target
$18.86Price Target Upside36.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bausch + Lomb Corporation News
PremiumCompany Announcements
Bausch + Lomb Reports Strong Q1 Growth
PremiumCompany Announcements
Bausch + Lomb Reports Robust Q1 2024 Growth
PremiumCompany Announcements
Bausch + Lomb Debuts Eye Health Innovations
PremiumCompany Announcements
Bausch + Lomb’s Breakthrough in Dry Eye ReliefBulls Say, Bears Say
Bulls Say
Financial GuidanceThe company reassures investors of its steady financial outlook, undeterred by currency fluctuations, and anticipates continued revenue growth excluding foreign exchange impacts.
Product Launch SuccessMiebo's launch is surpassing expectations with strong sales, making a significant contribution to the company's overall financial health.
Strategic Market PositionWith the successful integration of Xiidra and Miebo, the company secures a dominant position in the dry eye market, which could drive long-term competitive advantage and market share.
Bears Say
Competition And Market ShareRestasis average monthly total prescriptions saw a year over year decrease of 7.5%, suggesting the drug is losing ground to generic alternatives and could be a sign of weakening brand loyalty.
Financial OutlookConsensus EBITDA/EPS may be optimistic considering the potential impact of launch investment, foreign exchange headwinds, and a higher interest/tax rate on the company's profitability.
Prescription TrendsXiidra's monthly total prescriptions fell significantly in the recent months, indicating a possible decline in the drug's market share and sales potential.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $13.62 and its highest was $21.95 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Currently, no data Available
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Aug 01, 2024 which is in 88 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on May 01, 2024. The company reported $0.07 earnings per share for the quarter, the consensus estimate of $0.07 by $0.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is $0.14.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 350,992,250 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.07 in its last earnings report, expectations of $0.07. Following the earnings report the stock price went down -5.502%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Among the largest hedge funds holding Bausch + Lomb Corporation’s share is Goldentree Asset Management Lp. It holds Bausch + Lomb Corporation’s shares valued at 80M.
---
Bausch + Lomb Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.86 (36.08% Upside)
$18.86 (36.08% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 6.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.57%
12-Months-Change
Fundamentals
Return on Equity
-3.75%
Trailing 12-Months
Asset Growth
20.62%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch & Lomb Corp is a global eye health company dedicated towards protecting and enhancing the gift of sight for millions of people around the world. It holds portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
---
BLCO Company Deck
---
BLCO Earnings Call
Q1 2024
0:00 / 0:00
---
BLCO Stock 12 Months Forecast
Average Price Target
$18.86
▲(36.08% Upside)
Technical Analysis
Best Analysts Covering BLCO
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-3.38%
assigned a buy rating 3 days ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -3.38% per trade.
---